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Despite exposure levels estimated to be equivalent to smoking only 0.1-1.0 cigarettes per day,
exposure to environmental tobacco smoke (ETS) is estimated to increase the risk of death from
coronary heart disease (CHD) between 25 and 35% above the risk of nonexposed persons. This
surprisingly large risk associated with a seemingly small exposure has raised doubts about the
validity of attributing the increased CHD risk to ETS exposure. This paper reviews various biases
that have been hypothesized to account for the increased CHD risk associated with ETS in the
epidemiologic studies and characterizes the adverse effects of ETS on thrombosis, vascular
endothelium, and exercise tolerance observed in experimental studies of humans and laboratory
animals. None of the identified factors that has been proposed to introduce a spurious association
between ETS and heart disease seem to invalidate the epidemiologic findings, either separately or
in combination. In addition, experimental studies of ETS and heart disease demonstrate that acute
exposure of humans and other species to ETS affects platelet function, vascular endothelium, and
myocardial exercise tolerance at exposure concentrations widely prevalent in the workplace.
Because exposure to ETS affects multiple physiologic pathways, it appears biologically plausible
that ETS could cause the substantial increase in CHD risk that has been observed in epidemiologic
studies. Key words: atherosclerosis, cardiovascular disease, risk factor, smoking. - Environ Health
Perspect 107(suppl 6):853-858 (1999).
http.//ehpnet1.niehs.nih.gov/docs/1999/suppl-6/853-858howard/abstract. html
Background
Estimates of the number of deaths in the
United States from heart disease attributable to
exposure to environmental tobacco smoke
(ETS) range from 32,000 to 40,000 annually,
approximately two-thirds of the estimated
53,000-60,000 deaths from all causes attribu-
ted to ETS (1-3). Based on pooled analyses of
epidemiologic studies, nonsmokers exposed to
ETS in the workplace have an estimated car-
diovascular risk 1.35 times that ofthose not
exposed, whereas those exposed at home have a
cardiovascular risk 1.23 times that ofthe unex-
posed (4). Should these estimates be accurate,
ETS exposure would rank as the third leading
cause ofavoidable death in the United States
(1). In addition, these estimates ofcardiovas-
cular deaths from ETS are approximately 20%
ofthe estimated 180,000 cardiovascular deaths
from active smoking, the leading cause of
avoidable death in the Unites States (5).
The increased risk of cardiovascular
disease associated with ETS exposure has
been viewed as disproportionately large com-
pared to the risk caused by active cigarette
smoking, especially when ETS exposure is
considered in terms ofcigarette equivalents
(6-8). The National Research Council esti-
mates that nonsmokers exposed to ETS
absorb the equivalent of 0.1-1.0 cigarettes
actively smoked per day, based on urine coti-
nine measurements (9). Thus, nonsmokers
exposed to ETS absorb an estimated 1% of
the nicotine ofpeople actively smoking one
pack per day, yet they experience up to 50%
the excess risk of heart disease incurred by
active smokers (7).
This paper considers the apparent discrep-
ancy between the risk estimates for active and
passive smoking. First, it examines several
possible methodological problems or biases
that have been hypothesized to explain the
strength ofthe observed association between
ETS and heart disease, including publication
bias, residual confounding, and exposure mis-
classification. Second, it considers explana-
tions as to why the ETS/CHD (coronary
heart disease) relationship might be larger
than expected based on cigarette equivalents.
Within this section we discuss a) the magni-
tude ofthe association that might be expected
based on studies of active smoking; b) the
dose-response relationships measured
between ETS exposure and platelet function,
vascular endothelium, and cardiac exercise
tolerance in experimental studies; c) discrep-
ancies between ETS and mainstream smoke
regarding certain components ofETS expo-
sure that are not captured accurately by the
measure ofcigarette equivalents; and d) why
the effects ofETS on active smokers may dif-
fer from the effects on nonsmokers.
Bias, Confounding, and
Misclassification of Exposure
This first section examines various method-
ological considerations that could, in theory,
cause the epidemiologic studies to over- or to
underestimate the association between ETS
exposure and heart disease. One of these
issues (publication bias) relates to the general
scientific process, external to any particular
study, whereas other issues such as confound-
ing and misclassification of exposure affect
the magnitude ofthe association in specific
studies.
Publication Bias
It is possible that studies finding a significant
effect (or even nonsignificant effects in the
anticipated direction) are more likely to be
developed into manuscripts by investigators
and subsequently more likely to be accepted
for publication. This publication pattern is
referred to as publication bias. It has been
suggested that the omission from the litera-
ture of negative studies regarding ETS and
heart disease could bias meta-analyses upward
and cause a spurious association between ETS
and CHD (10-13).
The report by LeVois and Layard (10)
discusses publication bias most thoroughly.
The authors argue that the exclusion oflarge
unpublished studies, specifically theAmerican
Cancer Society's Cancer Prevention Study I
(CPS-I) and II (CPS-II) and the National
Mortality Followback Study, from the reports
estimating the impact ofETS on heart disease
(1-3) introduces publication bias. Using a
graphical approach to detect publication bias
(14), LeVois and Layard demonstrate that
the inclusion ofthese unpublished studies (at
the time ofLeVois and Layard's writing) pro-
vides evidence ofsuch bias. However, LeVois
and Layard rely on their own analyses ofthe
three studies to support their case. In their
analysis ofCPS-II, they emphasize the lack of
evidence that heart disease death rates are
increased among lifelong nonsmokers mar-
ried to smokers [relative risk (RR) = 0.97 for
men and 1.00 forwomen] (10).
More important is that CPS-II never
smokers married to current smokers do have
increased death rates from CHD (RR = 1.22
for men, 95% confidence intervals [CI]
1.07-1.40; and RR = 1.10 for women, 95%
CI = 0.97-1.45), as shown by Steenland et al.
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(15). Current exposure to ETS provides a
better index of exposure since some of the
adverse cardiovascular effects of tobacco
smoke are reversible.
With the 1996 Steenland et al. publica-
tion (15) describing the impact on cardiovas-
cular risk of ETS exposure in the CPS-II
cohort, the interpretable data from the largest
prospective cohort studies have now been
reported, making the argument ofpublica-
tion bias less plausible. More important, the
role ofpublication bias on the estimated risk
associated with ETS has been reviewed, and
found to be, at most, small (16). Because of
the large number ofpublished studies, the
inclusion or exclusion ofother unpublished
studies would have minimal effect on the
overall association between ETS exposure and
heart disease risk.
Confounding
It has been argued that individuals who report
exposure to ETS also have on average greater
exposure to other risk factors that place them
at excess risk for CHD (12,17,18). Lee (12)
argues that there are well over 100 factors that
have been reported to show a significant rela-
tionship with cardiovascular disease, and that
not all ofthese factors have been measured
and adjusted for in the studies reported. Some
ofthe epidemiologic studies of ETS adjust
only for age and sex; most do not capture or
control completely for other factors that may
contribute to risk. The resulting overestima-
tion of risk attributable to ETS is called
residual confounding.
Although residual confounding is of
concern, there is little to suggest that it con-
tributes more than a small fraction of the
observed association between ETS and CHD.
Few ofthe more than 100 factors associated
with increased CHD risk contribute indepen-
dently to the risk (19). The lifestyle factors
that independently affect CHD risk and are
associated with ETS exposure do not all affect
the ETS association in the same direction. For
example, alcohol consumption is more com-
mon among persons who report ETS expo-
sure but is generally associated with decreased
rather than increased CHD risk. Adjusting for
all measured covariates in the epidemiologic
studies ofETS generally causes either a small
increase or decrease in the observed associa-
tion. In the Nurses' Health Study, which has
the best potential to adjust for dietary factors,
the age-adjusted relative risk for CHD associ-
ated with ETS exposure was 1.97 (20).
Further adjustment for a broad array of risk
factors (alcohol intake, body mass index, his-
tory ofhypertension, diabetes mellitus, hyper-
cholesterolemia, menopausal status, current
use ofpostmenopausal hormones, past use of
oral contraceptives, vigorous exercise, fat
intake, vitamin E intake, aspirin use, parental
history of myocardial infarction [MI], and
father's occupation when the participant was
16 years ofage) reduced the excess relative risk
by only 26% to 1.71 (20). This list includes
most ofthe major risk factors for heart disease
(19). Residual confounding is unlikely to
account for the remaining 74% of the
unadjusted association.
MisclassificationofSmokingStatus
There is a well-known tendency for the
prevalence ofcigarette smoking to be under-
estimated when assessed by self-report
(21-23). In general, nonrandom misclassifi-
cation ofthe independent variables in analysis
will tend to bias estimates toward the null,
leading to the underestimation of the ETS/
CHD relationship. This bias toward the null
will be the case ifthe misclassification ofthe
risk factor is random, that is, ifpeople are as
likely to over report as to under report their
exposure to ETS. However, ifthe misclassifi-
cation is differential (i.e., not random), then
it is possible that misclassification can bias an
estimate away from the null hypothesis.
It has been suggested that assessment of
the effects of ETS exposure, independent of
active smoking, is a case in which differential
misclassification could be ofconcern (21). It
is possible that a larger proportion ofactive
smokers who incorrectly report that they are
nonsmokers may also report that they are
exposed to ETS. In this case, an analysis of
the impact ofETS among reported nonsmok-
ers would include a larger proportion of
active smokers among those reporting expo-
sure to ETS than among those not reporting
such an exposure. Since the potential impact
ofactive smoking is substantially larger than
the impact ofETS, this relative enrichment
of those reporting exposure to ETS will
increase the riskofdisease in that group.
This misclassification is likely to play a
relatively minor role in the estimation ofthe
ETS/CHD association. First, its extent has
been shown to be relatively small. CARDIA
(Coronary Artery Risk Development in
Young Adults) is a longitudinal study ofthe
evolution ofcardiovascular risk factors in a
cohort ofyoung adults. The study includes
5,115 adults age 18-30 at baseline (con-
ducted in 1985-1986) sampled from four
communities in the United States.
Approximately one-fourth of the sample is
African American male, African American
female, white male, and white female. This
study is one ofthe few large population-based
cohorts to confirm self-reported active smok-
ing with a serum cotinine assay. In this
report, the biracial (black and white)
CARDIA population is limited to 3,445 non-
smoking men and women age 18 to 30 years.
Although the participants are somewhat
younger than the participants in the larger
epidemiologic studies used to establish the
ETS/CHD association, the CARDIA study
offers one ofthe few opportunities to assess
the misclassification ofreported active smok-
ing and ETS exposure. Self-reported active
smoking rates underestimated the true smok-
ing rate, as assessed by serum cotinine, byonly
1.3% overall (although the misclassification
rate was somewhat higher in subgroups, such
as 3.3% in African Americans with less than a
high school education) (23). Thus, few active
smokers reported themselves to be nonsmok-
ers, lessening concern that a large number of
those classified as nonsmokers exposed to ETS
are in fact active smokers. More important,
the magnitude ofrelative risk ofheart disease
associated with active smoking (averaging
approximately 1.8 across all ages) is relatively
low, and the potential consequences ofthis
type oferror are small, particularly in compar-
ison to the potential consequences in studies
of ETS and lung cancer. This smaller effect
has led Lee, who initially raised this concern
in the assessment ofthe ETS/lung cancer rela-
tionship (21), to conclude that this bias could
not explain the overall estimate ofthe relative
riskof1.28. At most, misclassification bias has
only a very minor role in affecting the
ETS/CHD association.
OtherBiases
Those participants in case-control studies
with a disease (cases) may be more likely to
remember the exposure of interest (ETS)
than those without the disease (controls),
which introduces a recall bias (12). It is also
possible that surrogates in case-control
studies may misreport exposures differen-
tially, leading to an overestimation of the
ETS/CHD relationship (13). With growing
evidence from prospective cohort studies (in
which exposure is established directly by the
participant prior to the development ofdis-
ease) to describe the ETS/CHD relationship,
recall bias and surrogate reporting effects are
unlikely to have a significant effects on risk
estimates. In general, misclassification ofthe
disease status will bias results toward the
null (in this case underestimating the
ETS/CHD relationship). Springall has spec-
ulated that persons with ETS exposure may
differentially be diagnosed as having heart
disease because of lifestyle or occupational
factors associated with heart disease (13).
However, this seems implausible given the
routine nature of diagnostic tests for heart
disease and the lack ofevidence to support
differential misclassification.
SummaryofPotentialBiasingEffects
Although several potential biases could cause
an over- or underestimation ofthe ETS/CHD
effect, these seem unlikely, individually or in
combination, to account for the observed
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association. The potential impact ofany of
these individual factors is small, largely
speculative, and, as illustrated by alcohol con-
sumption, not uniformly in one direction.
Even though it is theoretically possible that
the combined effect of these factors could
explain the ETS/CHD relationship, the lack
ofevidence for any individual factor makes it
unlikely that an aggregate effect can be
invoked to explain the ETS/CHD association.
At most, the composite impact ofthese biases
would only marginally decrease the estimated
effect ofETS.
Potential Explanations for the
ETS/CHD Relationship
The next section ofthis paper examines why
the ETS/CHD relationship might be larger
than expected based on cigarette equivalents.
It considers extrapolations from studies of
active smoking, experimental studies that
measure the acute effects ofETS on platelet
function, vascular endothelium, and exercise
tolerance, and differences in the composition
ofETS and mainstream smoke that compli-
cate extrapolation from active smoking to
ETS based on cigarette equivalents.
Extrapolation fromStudies
ofActiveSmoking
Many studies describe a dose-response
relationship between the risk of CHD and
the number ofcigarettes smoked per day by
active smokers (24). Data from the 1983
Surgeon General's report on smoking and
cardiovascular disease can be used to predict
the expected hazard ratio at a low-dose expo-
sure of 0.1-1.0 cigarettes per day [Table 12
in Section 3 ofthe U.S. DHHS report (24)].
This report summarizes nine studies in males,
providing the mortality ratio for coronarydis-
ease in relation to the number ofcigarettes
consumed. We used linear regression to
describe the relationship between cigarette
use and CHD mortality in the seven studies
that report risk in relation to cigarettes per
day (allowing more direct comparison to the
dose in ETS smoking) and three or more lev-
els ofsmoking (allowing meaningful regres-
sion analysis). For this analysis we assumed a
linear relationship between cigarette use and
the mortality ratio for CHD. For each study,
the cigarette exposure was described as the
mid-point ofthe range ofexposure (for exam-
ple, for those smoking 1 to 9 cigarettes per
day, a value of [1 + 9]/2 or 5 cigarettes per
day was used). For the upper open interval, a
value one-halfthe range ofthe second highest
interval above the lower limit was used. For
example, ifthe second highest interval was 21
to 39 cigarettes per day, with a range of 18,
then the value of49 (9 above the lower limit
of the top interval) was used in the analysis.
Linear regression was then used to estimate
the expected value of the mortality ratio at
0.55 cigarettes per day (the midpoint ofthe
interval 0.1 to 1.0 cigarettes per day). The
expected mortality ratio ranges from 1.13 to
1.47 across the seven studies, with an overall
average of 1.32, not substantially different
from the projection expected based on ciga-
rette equivalent exposures to ETS. A similar
approach by Law et al. (7) also found a slight
difference between the expected RR esti-
mates, based on projections from active
smokers, and the observed RR estimates,
based on studies ofETS exposure.
Extrapolations based on the CHD risk of
active smokers are subject to a number of
uncertainties, however. Although the RR for
CHD is strongly and inversely related to age
(25), these calculations are based on age-
adjusted, rather than age-specific RR esti-
mates for the active smokers. Similarly, our
projection and that of Law et al. (7) are
based on studies of active smoking in the
1950s and 1960s, when the association
between cigarette smoking and CHD in the
United States was weaker than it became by
the 1980s (25). Finally, there is uncertainty
about the appropriate intercept for these
mathematical models. Nevertheless, these
extrapolated risks are closer to the directly
measured risks ofETS exposure reported in
the epidemiologic literature (4).
Experimental Studies ofETS Exposure
Experiments in both humans and animals
demonstrate that ETS exposure adversely
affects several pathways involved in the
pathogenesis of CHD (26). The experimen-
tal studies are an important compliment to
the epidemiologic studies because they mini-
mize the potential for confounding by meas-
uring changes within individuals before and
after acute ETS exposure and because the
level and duration ofETS exposure are rea-
sonably well characterized. The experiments
are particularly informative regarding mecha-
nism, dose response, and biologic plausibility.
These studies have measured effects on
platelets, thrombosis, vascular endothelium,
and exercise tolerance. In particular the
effects ofETS on platelets might amplify the
adverse cardiovascular effects of ETS above
those expected based on cigarette equivalents.
Platelets andthrombosis. The acute event
that precipitates many MIs (heart attacks) is
the formation of a thrombus or clot that
obstructs the arterial blood supply to a por-
tion of the heart (27). ETS exposure
enhances the activation and aggregation of
platelets, which have an initiating role in
thrombus formation. The inhibition of
platelet aggregation by aspirin and other
antiplatelet drugs is thought to underlie the
prevention ofcardiovascular events in high-
risk populations (28,29).
At least five experimental studies have
measured the acute effects of ETS exposure
on platelet function among healthy, non-
smoking human volunteers exposed for 15 to
60 min at ETS concentrations comparable to
those in many bars, restaurants, and other
public places (Table 1). These studies meas-
ured changes in platelet aggregation, platelet
sensitivity to antiaggregatory prostaglandins
(PGI2) or concentrations of proaggregatory
prostaglandins such as thromboxane B2. For
example, Kritz and Sinzinger (30) observed
an increase in markers of platelet activation
and a decrease in platelet sensitivity to PGI2
among 12 nonsmokers exposed for 20-min
in an 18 m3 room in which 30 Gitanes had
recently been smoked. The hypercoagulable
state demonstrated among nonsmokers
acutely exposed to ETS (30-34) resembles
the acute changes in smokers who consume
one or two cigarettes after a period ofabsti-
nence (35-43). Schmid et al. (31) found
that, prior to ETS exposure, the platelets of
nonsmokers were significantly less activated
than those ofsmokers, whereas after 20 min
exposure to ETS, platelet activation increased
among the nonsmokers exposed to ETS
(p < 0.01) but remained constant among the
active smokers (p > 0.05). The effects of
tobacco smoke exposure upon platelet aggre-
gation and production of thromboxane B2
appear to be mediated by factors other than
nicotine (44).
Experimental exposure of rabbits (45)
and rats (46) to low concentrations ofETS
has also been shown to shorten bleeding time,
another measure ofplatelet activation (26).
The average concentrations ofair nicotine,
carbon monoxide, and total particulate con-
centrations in rabbits exposed to low-dose
ETS were 30 pg/m3, 18.8 ppm, and 4.0 ppm,
respectively. Bleeding time was shortened as
much in rabbits exposed to low as to higher
concentrations ofETS (45). Another experi-
ment involving New Zealand white rabbits
demonstrated that 15 min of exposure to
sidestream cigarette smoke significantly
increased tracheal epithelial production of
several prostaglandins that affect platelet
aggregation including prostaglandin (PG)E2,
6-keto F,a, and thromboxane B2) (47).
Effects on vascular endothelium. Injury to
the endothelial layer of blood vessels is
another mechanism by which relatively small
exposures to ETS could contribute to the ini-
tiation or promotion ofatherogenesis (48).
ETS profoundly damages the vascular
endothelium in animal models, inducing
bleeding, microvillus-like projections from
the luminal surface, and the presence of
micro-thrombi in low shear areas ofrats (49).
Experimental data on vascular endothelial
injury are more limited in humans, although
Davis et al. (32) (Table 1) found an increase
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Table 1. Experimental studies of ETS effects on platelets, endothelial cells, and cardiac performance in humans.
Reference Place Population Exposure Duration Results
Effects on platelets
Kritzand Sinzinger, Vienna, Austria 12 nonsmokers 30 Gitanes in 20 min platelet activation
1996 (30) 18-m3 room 4. plateletsensitivity toPGI2
Schmid et al., Vienna, Austria 12 nonsmokers, 30 Gitanes in 60 min 10-50% acute 1 in plasma thromboxane B2
1995(31) age 20-32 18-m3 room Mostly reversed in 6 hr
Measurements in nonsmokers afterrepeated
exposures resembled those ofsmokers
Davis etal., Kansas City, KS 10 nonsmoking men, Hospital corridor 20 min 1 in plateletaggregate ratio from 0.87 to 0.78
1989(32) age 23-49 next to smokers (reflects 1formation ofplateletaggregates)
Burghuber et al., Vienna, Austria 9 nonsmoking men, 30 Gitanes in 20 min 1 plateletsensitivity to PGI2
1986 (33) age 25-40 18-m3 room
Sinzinger and Vienna, Austria 9 nonsmokers, 30 Gitanes in 15 min . plateletsensitivity toantiaggregatory
Kefalides, 1982(34) age 24-30 18-m3 room prostaglandins
Effects on endothelial cells
Davis et al., Kansas City, KS 10 nonsmoking men, Hospital corridors 20 min I in circulating anuclear endothelial cell car-
1989 (32) age 23-49 nextto smokers casses from mean ± SD 0.28 ± 0.9 to 3.7 ± 1.1
Effects on cardiac performance
Leone et al., Italy 19 nonsmoking men 15-20 cigarettes 2-hr exposure No effect on 9healthy men
1991 (60) (9 healthy, 10 Ml) smoked in a followed by exer- In men with hx Ml peakexercise power4 33%
60-m3 room cise stress test Time to recovery 1 41%
McMurray etal., North Carolina, 8 healthywomen Machine smoking Exercise stress test Time to exhaustion 4. 8%
1989(61) (4 smokers, 4 non- 2 cigarettes per in room where Max oxygen uptake 4. 10%
smokers) 6 min 15-20 cigar-
ettes smoked
Aronow, 1978(62) long Beach, CA 10 men (8 ex-smokers, 2 hr in 30.8-m3room Bicycle ergom- Time to angina 138% in unventilated
2 smokers) with with 3 companions etrytest room and 122% in well ventilated room
stable exertional who smoked
angina 5 cigarettes
SD, standard deviation.
in circulating anucleated endothelial cells in
response to ETS exposure. These circulating
cells, which may reflect acute endothelial
desquamation, become almost as abundant in
persons exposed to ETS as in active smokers.
Exposure of nonsmokers to ETS might also
contribute to vascular injury by causing an
acute decrease in serum ascorbic acid and
protein sulfhydryl group concentrations,
accelerated lipid peroxidation, and accumula-
tion oflow density lipoprotein cholesterol in
macrophages (50).
Passive smoke exposure has been shown
to accelerate arteriosclerotic plaque develop-
ment in experimental studies of cockerels
(51-54), rabbits (55,56), and rats (57).
There is some evidence from cockerels that
the size of the plaques is influenced more
than the number of plaques (52) and that
components of the vapor phase ofETS may
accelerate atherogenesis more than does the
tar fraction (53,54). Exposure to the side-
stream smoke from even one cigarette was
sufficient to promote atherosclerotic plaque
development in cockerels (51). These adverse
effects on vascular endothelium and plaque
development observed in the experimental
studies could contribute to the dose-
dependent impairment ofvascular dilatation
triggered by the endothelium, that has been
seen in some (58), but not all (59),
observational studies of otherwise healthy
young adults exposed to ETS.
Effects on cardiac exercise tolerance.
Table 1 lists three experimental studies
involving humans. These studies measured
changes in exercise tolerance or time to
angina in patients with or without a history
of cardiovascular disease following exposure
to ETS (60-62). The reduction in exercise
tolerance was greater among men with a
history of a past MI (60) and in those with
stable exertional angina (61) than among
healthy women in Italy (62). In all these
studies, cardiac response to exercise was
significantly worsened by ETS exposure.
Inapproprate Representaion of
Exposure byCigarette Equivalents
Measurements ofurine cotinine in active and
passive smokers show that reliance on ciga-
rette equivalents as the sole index oftobacco
smoke exposure may substantially underesti-
mate exposure to other constituents ofETS
and misrepresent its cardiovascular patho-
genicity (9). The composition of ETS is
complex, containing over 4,000 chemical
compounds with varying representation in
sidestream smoke (63). For example,
between 2.1 and 46 mg of nicotine (the
premetabolite ofcotinine) is contained in the
undiluted mainstream smoke of each
cigarette. However, the concentration of
nicotine is between 1.3 and 21 times greater
in undiluted sidestream than in mainstream
smoke. Other chemicals have even higher
proportionate representation in sidestream
smoke. For example, the estimates of the
ratio of N-nitrosodimethylamine in side-
stream to mainstream smoke range from 20
to 130 times, and benzo[a]pyrene ranges
from 2.5 to 20 times (63). Based on the
lower limits ofbenzo[a]pyrene, it is nearly
twice as concentrated as nicotine in side-
stream smoke. The lack of symmetry
between nicotine and other components of
mainstream and sidestream smoke is com-
pounded in the cotinine studies by differ-
ences in the absorption and metabolism of
nicotine. Thus, estimates ofexposure based
on a single component ofETS may misrep-
resent the extent of exposure to other
components.
Some compounds that are over-
represented in sidestream smoke may con-
tribute biologically to the development of
clinical coronary events. For example, Glantz
and Parmley (26) reported that several ani-
mal studies have established a role ofaromatic
hydrocarbons (including benzo[alpyrene)
with the development of atherosclerosis
through mechanisms of cell injury and
hyperplasia.
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EffectsofETS inSmokersand
Nonsmokers
Some studies suggest that active smokers may
be less adversely affected by ETS than non-
smokers. Glantz and Parmley (26) have
observed that the concentrations ofcertain
antioxidants are much higher in the lungs of
hamsters exposed to ETS and in active smok-
ers than in lungs ofthose not exposed chroni-
cally to cigarette smoke. These researchers
hypothesize that chronic exposure to cigarette
smoke may stimulate protective scavenging
systems, and therefore smokers may be less
sensitive to damage from free radicals in ETS
than nonsmokers. They also describe greater
activation oflung neutrophils in nonsmokers
than in smokers after ETS exposure.
Inappropriately activated neutrophils release
oxidants involved in tissue damage. Although
data are not available to strongly support this
potential hypothesis, it may be speculated
that the absence ofcompensatory mecha-
nisms may cause nonsmokers to be more
susceptible to ETS than activesmokers.
Conclusions
We find little or no evidence that the
association between ETS and heart disease
observed in numerous epidemiologic studies
can be attributed to chance or to various biases
that have been proposed. A sufficient number
oflarge epidemiologic studies have now been
identified that chance and publication biases
have become implausible. Even ifadditional
studies were reported or conducted in the
future, these would be unlikely to cause a sub-
stantial change in the pooled RR estimate.
Confounding also seems unlikely to explain
more than a small fraction of the observed
association. All ofthe epidemiologic studies of
CHD and ETS exposure control for age and
sex. Studies that have adjusted for additional
factors have not found large or consistent
changes in their relative risk estimates. Even
the Nurses' Health Study, which has the most
extensive data available to control for diet and
other factors, found only a 26% reduction in
the excess relative risk after adjusting for 11
covariates (20). The experimental studies of
ETS and heart disease that are much less sus-
ceptible to confounding or misclassification of
exposure than the epidemiologic studies also
demonstrate changes in platelet function, vas-
cular endothelium, and myocardial exercise
tolerance in response to well-defined exposures
to ETS.
There is legitimate uncertainty about the
extent to which the association between ETS
and heart disease in the epidemiologic studies
exceeds what would be expected, based on a
linear extrapolation from active smokers.
Although the concentration ofserum cotinine
in nonsmokers exposed to ETS is between 0.1
and 1% ofthe cotinine concentration in active
smokers, there is no evidence that nicotine
alone is the main contributor to heart injury or
that nicotine absorption accurately reflects the
uptake ofother toxicants from ETS.
The experimental studies ofETS and heart
disease in humans, although small, provide an
unusual resource rarely available for industrial
pollutants. These experiments demonstrate
that it is biologically plausible that ETS affects
platelet function, vascular endothelium, and
myocardial exercise tolerance at exposure con-
centrations widely prevalent in the workplace.
These experimental studies share two short-
comings: a) they are based on relatively few
study subjects; and b) because oftime limita-
tions, they tend to focus on the effects ofacute
(rather than chronic) exposure to a relatively
few cigarettes. However, although these studies
are based on fewsubjects, theygenerally have a
sufficient number to establish the significant
effect ofETS exposure. In addition, the acute
effects observed may increase the risk ofcoro-
nary events both through acute (such as
platelet aggregation) and chronic (such as
plaque formation) mechanisms. There is also a
possibility that a threshold effect may exist,
such as leave open the possibility ofathreshold
effect such as could be observed by increased
coaguability after passive smoke exposure.
Because ETS affects multiple physiologic
pathways, it is entirely plausible that the
dose-response relationship is not linear over
the entire range ofexposure.
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